ABSTRACT BACKGROUND Long-term safety and efficacy for everolimus-eluting stents (EES) versus those of sirolimus-eluting
. In view of the overall low frequency of stent thrombosis, large sample sizes (10) or longterm follow-up are needed to accurately estimate treatment differences between stent types (11) (12) (13) (14) . Furthermore, the timing of the primary endpoint in a clinical study comparing 2 treatments should reflect a time point where a potential true and longlasting difference can be predicted. Primary endpoints are conventionally assessed after 12 months, which may be insufficient to predict long-term clinical outcome (12, 13) . The only study powered to assess the risk of stent thrombosis, the PROTECT (Pa- Jensen et al.
Everolimus-Versus Sirolimus-Eluting Stents F E B R U A R Y 2 3 , 2 0 1 6 : 7 5 1 -6 2 EES (Xience V, Abbott Vascular, Santa Clara, California); the Promus (Boston Scientific, Marlborough, Massachusetts) Xience V (Abbott) everolimus-eluting coronary stent system; or SES (Cypher Selectþ, Cordis). An independent organization generated the allocation sequence by computer, in which patients were stratified by sex and presence of diabetes. Patients were assigned to treatment through an automated telephone allocation service. Although operators were unblinded, all individuals analyzing outcome data were masked to treatment assignment. OUTCOME MEASURES AND DATA MANAGEMENT. Definitions of endpoints are provided elsewhere (7).
Pre-specified follow-up examinations were at 9 and 18 months and then at 2, 3, and 5 years. We assessed a composite endpoint (safety and efficacy) with safety Values are mean AE SD or n (%).
Jensen et al.
Everolimus-Versus Sirolimus-Eluting Stents reinterventions. Data for mortality, hospital admission, coronary angiography, repeated PCI, and coronary artery bypass surgery were obtained for all randomly allocated patients from Danish registry data. This method has been described in detail in previous SORT OUT III-V publications (7, 8, 20 ). An independent event committee, masked to treatment group assignment during the adjudication process, 
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Everolimus-Versus Sirolimus-Eluting Stents STATISTICAL ANALYSIS. The trial was powered for assessing noninferiority of EES to SES with respect to the primary endpoint at 9 months. The sample size of 1,339 in each group assumed 0% lost-to-follow-up rate, given the use of the Civil Registration System.
For the present study, we performed 2-sided 95% confidence intervals (CIs) and 2-sided p values for superiority for all endpoints. Distributions of continuous variables were compared between study groups using the 2-sample Student t test (or Cochran t test for cases of unequal variance) or the Mann-Whitney U test, depending on whether the data followed a normal distribution. Distributions of categorical variables were compared using the chi-square test. In analyses of every endpoint, follow-up continued until the date of an endpoint event, death, emigration, or 60 months after stent implantation, whichever came first. Cumulative incidence functions were computed taking into account death (and in a sensitivity analysis also stent thrombosis) as a competing risk (21) .
We used Gray's test for comparing the cumulative incidence functions and Cox regression to determine the cause-specific hazard ratios (HRs). Patients treated with the SES were used as the reference group for overall and subgroup analyses. Hazard ratios were calculated for major adverse cardiac events at 5-year follow-up for pre-specified patient subgroups (based on baseline demographic and clinical characteristics).
The intention-to-treat principle was used in all analyses. A 2-sided p value of <0.05 was considered statistically significant. Analyses were conducted using SAS version 9.2 software (Cary, North Carolina).
RESULTS
A total of 2,774 patients with 3,584 lesions were randomly assigned to receive either EES (1,390 patients with 1,805 lesions) or SES (1,384 patients with Table 1 . Table 2 ). In Figure 1 , the Kaplan-Meier We performed a post hoc analysis of MACE, MI, and TLR, where the patients were censored at the time of the stent thrombosis event (before TLR). This analysis revealed that the observed differences between EES and SES were no longer present, that is, the higher frequency of stent thrombosis events in the SES group were the main cause of the observed differences between EES and SES ( Table 4) .
Findings for the combined endpoint MACE were consistent across pre-specified, stratified analyses ( Figure 3) , including diabetes.
DISCUSSION
The SORT OUT IV trial provides 5-year head-to-head randomized comparison of EES versus SES. Present data show that, in comparison to SES, EES had a better long-term safety and efficacy profile. Our findings also demonstrate that treatment with EES was associated with a 20% reduction in MACE rate, which was largely attributable to a lower risk of very late definite stent thrombosis (Central Illustration).
MACE rate did not differ significantly within the first year, which is the most common time point used for assessing the primary endpoint in head-to-head comparisons of drug-eluting stents. However, from year 1 through 5 the MACE rate was lower with EES than for SES. vs. 2.5%, respectively). This is in accordance with the STEMI ¼ ST-segment elevation myocardial infarction; other abbreviations as in Figure 1 .
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Jensen et al. The optimal duration of dual-antiplatelet therapy (DAPT) after DES implantation has been studied and debated, and its risks and benefits may vary according to DES generation. A meta-analysis (27) showed that short-term DAPT had overall lower rates of bleeding yet higher rates of stent thrombosis than long-term DAPT; the latter effect was significantly attenuated with the use of second-generation DES.
The very low rate of very late stent thrombosis with EES compared with a higher rate (on aspirin monotherapy) with SES in SORT OUT IV demonstrates that it is not only the duration of DAPT but also the type of DES that is important for increasing the safety and reducing the risk of stent thrombosis.
Furthermore, the importance of long-term followup in randomized studies comparing DES is critical to Jensen et al.
Everolimus-Versus Sirolimus-Eluting Stents Like most stent trials, the SORT OUT IV trial was designed as a single-blinded study, and we believe that the lack of double-blindness would not influence the results, as all endpoints were objective and determined by an event committee that was blinded to treatment group assignment during the adjudication process. Therefore, we expect that the event rate in our study was representative of the real event rate among this patient population. Our study used patient-driven event detection based on Danish registries (18, 30) . This registry-based randomized clinical trial design has been used in all SORT OUT trials and in the TASTE (Thrombus Aspiration During STSegment Elevation Myocardial Infarction) trial (31) and has received substantial interest as a way of undertaking large-scale, independent clinical trials.
Advantages of this approach include a substantial reduction in the expense associated with a randomized trial because we were able to use the established registry infrastructure. Moreover, the study design provides data that are more comparable to real-life situations because of the absence of study-related interventions. Like any conventional randomized trial, the SORT OUT trials use independent endpoint committee adjudication.
STUDY LIMITATIONS. Although the Danish health care databases capture events of sufficient severity for patients to seek medical attention, these records might underestimate event rates compared with follow-up by dedicated trial staff (32) . However, this situation should not bias differences detected between treatment groups, and the negligible loss to follow-up probably compensated for this potential limitation. Odense C, Denmark. E-mail: okkels@dadlnet.dk.
CONCLUSIONS

R E F E R E N C E S
PERSPECTIVES COMPETENCY IN PATIENT CARE AND PROCEDURAL
SKILLS:
The rate of major adverse cardiovascular events is lower in patients with stable ischemic heart disease treated with everolimus-eluting coronary stents than in those treated with sirolimus-coated stents over 5 years, attributable largely to a lower rate of late stent thrombosis.
TRANSLATIONAL OUTLOOK: Future research should address the pathophysiology of late stent thrombosis in patients with drug-eluting coronary stents and determine whether these stents differ from thrombotic events occurring within the first year after deployment.
